Literature DB >> 30206757

Activation of PD-1 Protects Intestinal Immune Defense Through IL-10/miR-155 Pathway After Intestinal Ischemia Reperfusion.

Xu-Yu Zhang1, Su Guan2, Hu-Fei Zhang1, Rui-Yun Li1, Zi-Meng Liu3.   

Abstract

BACKGROUND: To date, mechanisms of intestinal immunoglobulin (Ig) dysfunction following intestinal ischemia/reperfusion (I/R) remain unclear. Programmed death 1 (PD-1) is associated with immune responses of lymphocytes. AIM: We aimed to verify the hypothesis that activation of PD-1 may improve intestinal immune dysfunction by regulating IL-10/miR-155 production after intestinal IR injury.
METHODS: Intestinal I/R injury was induced in mice by clamping the superior mesenteric artery for 1 h followed by 2-h reperfusion. PD-L1 fusion Ig, anti-interleukin (IL)-10 monoclonal antibody (mAb), and microRNA (miR)-155 agomir were administered. PD-1 expression, IL-10 mRNA, and protein expression in Peyer's patches (PP) CD4+ cells were measured. MiR-155 levels, tumor necrosis factor (TNF)-α and IL-1β concentration, and activation-induced cytidine deaminase (AID), a key enzyme for intestinal immune antibodies, in PP tissues were measured, respectively. Importantly, the production and cecal bacteria-binding capacity of IgA and IgM were detected.
RESULTS: Intestinal I/R led to decreased PD-1 expression, imbalanced production, and impaired bacteria-binding capacity of IgA and IgM. Activating PD-1 by PD-L1 Ig facilitated IL-10 synthesis, then decreased miR-155 levels, and subsequently promoted AID expression and reduced TNF-α, IL-1β concentration. Upregulation of AID improved the disruptions of intestinal immune barrier caused by IgA and IgM dysfunction. Anti-IL-10 mAb and miR-155 agomir abolished the protective effects of PD-L1 Ig on the intestinal immune defense.
CONCLUSION: Activation of PD-1 with PD-L1 Ig relieves intestinal immune defensive injury through IL-10/miR-155 pathway following intestinal I/R attack. PD-1, IL-10, and miR-155 may be potential targets for the damages of intestinal barrier and immunity.

Entities:  

Keywords:  Interleukin-10; Intestinal mucosa; Programmed cell death 1 receptor; Reperfusion injury; microRNA

Mesh:

Substances:

Year:  2018        PMID: 30206757     DOI: 10.1007/s10620-018-5282-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut.

Authors:  Shimpei Kawamoto; Thinh H Tran; Mikako Maruya; Keiichiro Suzuki; Yasuko Doi; Yumi Tsutsui; Lucia M Kato; Sidonia Fagarasan
Journal:  Science       Date:  2012-04-27       Impact factor: 47.728

Review 2.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation.

Authors:  D Jankovic; D G Kugler; A Sher
Journal:  Mucosal Immunol       Date:  2010-03-03       Impact factor: 7.313

3.  Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury.

Authors:  Haofeng Ji; Xiuda Shen; Feng Gao; Bibo Ke; Maria Cecilia S Freitas; Yoichiro Uchida; Ronald W Busuttil; Yuan Zhai; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 4.  Role of PD-1 in regulating acute infections.

Authors:  Keturah E Brown; Gordon J Freeman; E John Wherry; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2010-04-27       Impact factor: 7.486

5.  The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.

Authors:  Wenjun Liao; Hua Zheng; Sha Wu; Yanmei Zhang; Wei Wang; Zili Zhang; Chenfei Zhou; Hongjun Wu; Jie Min
Journal:  Am J Nephrol       Date:  2017-10-26       Impact factor: 3.754

6.  IL-10 deficiency increases renal ischemia-reperfusion injury.

Authors:  Xin Wan; Wen Juan Huang; Wen Chen; Hong-Guang Xie; Pan Wei; Xin Chen; Chang-Chun Cao
Journal:  Nephron Exp Nephrol       Date:  2014-10-31

7.  Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats.

Authors:  Xu-Yu Zhang; Zi-Meng Liu; Shi-Hong Wen; Yun-Sheng Li; Yi Li; Xi Yao; Wen-Qi Huang; Ke-Xuan Liu
Journal:  Anesthesiology       Date:  2012-05       Impact factor: 7.892

8.  ATP-gated ionotropic P2X7 receptor controls follicular T helper cell numbers in Peyer's patches to promote host-microbiota mutualism.

Authors:  Michele Proietti; Vanessa Cornacchione; Tanja Rezzonico Jost; Andrea Romagnani; Caterina Elisa Faliti; Lisa Perruzza; Rosita Rigoni; Enrico Radaelli; Flavio Caprioli; Silvia Preziuso; Barbara Brannetti; Marcus Thelen; Kathy D McCoy; Emma Slack; Elisabetta Traggiai; Fabio Grassi
Journal:  Immunity       Date:  2014-11-13       Impact factor: 31.745

Review 9.  New insights in intestinal ischemia-reperfusion injury: implications for intestinal transplantation.

Authors:  Kaatje Lenaerts; Laurens J Ceulemans; Inca H R Hundscheid; Joep Grootjans; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  Curr Opin Organ Transplant       Date:  2013-06       Impact factor: 2.640

10.  TGF-β1 improves mucosal IgA dysfunction and dysbiosis following intestinal ischaemia-reperfusion in mice.

Authors:  Xu-Yu Zhang; Zi-Meng Liu; Hu-Fei Zhang; Yun-Sheng Li; Shi-Hong Wen; Jian-Tong Shen; Wen-Qi Huang; Ke-Xuan Liu
Journal:  J Cell Mol Med       Date:  2016-01-28       Impact factor: 5.310

View more
  3 in total

1.  Molecular Mechanisms Underlying Intestinal Ischemia/Reperfusion Injury: Bioinformatics Analysis and In Vivo Validation.

Authors:  Fengshou Chen; Dan Wang; Xiaoqian Li; He Wang
Journal:  Med Sci Monit       Date:  2020-12-08

Review 2.  miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis.

Authors:  Jing Zhou; Jialing Liu; Yangyang Gao; Liwei Shen; Sheng Li; Simin Chen
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

3.  Protective effect of ghrelin on intestinal I/R injury in rats.

Authors:  Meng Jiang; Shengxia Wan; Xiaoyong Dai; Youwen Ye; Wei Hua; Guoguang Ma; Xiufeng Pang; Huanhuan Wang; Bin Shi
Journal:  Open Med (Wars)       Date:  2022-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.